Filaggrin loss-of-function mutations and incident cancer: A population-based study

British Journal of Dermatology

Volumn 171, Issue 6, 2014, Pages 1407-1414

  Skaaby, T ^a   Husemoen, L L N ^a   Thyssen, J P ^b   Meldgaard, M ^b   Thuesen, B H ^a   Pisinger, C ^a   Jorgensen T ^a,c,d   Carlsen, K ^a   Johansen, J D ^b   Menne T ^b   Szecsi, P B ^b   Stender, S ^b   Linneberg, A ^a,c  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FILAGGRIN; LIPID; INTERMEDIATE FILAMENT PROTEIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BREAST CANCER; BRONCHUS CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; GENOTYPE; HEAD AND NECK CANCER; HUMAN; ICD-10; INVESTIGATIVE PROCEDURES; LOSS OF FUNCTION MUTATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NONMELANOMA SKIN CANCER; PHYSICAL ACTIVITY; PROSTATE CANCER; SKIN CANCER; SMOKING HABIT; UROGENITAL TRACT CANCER; UTERUS CANCER; WILD TYPE; ADOLESCENT; GENETICS; HETEROZYGOTE; HOMOZYGOTE; MIDDLE AGED; MUTATION; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84919459159     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12969     Document Type: Article

References (31)

1. Thyssen JP, Godoy-Gijon E, Elias PM,. Ichthyosis vulgaris: the filaggrin mutation disease. Br J Dermatol 2013; 168: 1155-66.
2. Irvine AD, McLean WH, Leung DY,. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011; 365: 1315-27.
3. Thyssen JP, Thuesen B, Huth C, et al,. Skin barrier abnormality caused by filaggrin (FLG) mutations is associated with increased serum 25-hydroxyvitamin D concentrations. J Allergy Clin Immunol 2012; 130: 1204-7.
4. Skaaby T, Husemoen LL, Martinussen T, et al,. Vitamin D status, filaggrin genotype, and cardiovascular risk factors: a Mendelian randomization approach. PLoS One 2013; 8: e57647.
5. Yin L, Ordonez-Mena JM, Chen T, et al,. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis. Prev Med 2013; 57: 753-64.
6. Ross-Hansen K, Ostergaard O, Tanassi JT, et al,. Filaggrin is a predominant member of the denaturation-resistant nickel-binding proteome of human epidermis. J Invest Dermatol 2014; 134: 1164-6.
7. Thyssen JP, Linneberg A, Carlsen BC, et al,. A possible association between a dysfunctional skin barrier (filaggrin null-mutation status) and diabetes: a cross-sectional study. BMJ Open 2011; 1: e000062.
8. Danaei G, Vander HS, Lopez AD, et al,. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005; 366: 1784-93.
9. Colotta F, Allavena P, Sica A, et al,. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-81.
10. Grivennikov SI, Karin M,. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010; 20: 65-71.
11. Olsen MH, Hansen TW, Christensen MK, et al,. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 2007; 28: 1374-81.
12. Jorgensen T, Borch-Johnsen K, Thomsen TF, et al,. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 2003; 10: 377-86.
13. Berg ND, Husemoen LL, Thuesen BH, et al,. Interaction between filaggrin null mutations and tobacco smoking in relation to asthma. J Allergy Clin Immunol 2012; 129: 374-80, 380.
14. Husemoen LL, Fenger M, Friedrich N, et al,. The association of ADH and ALDH gene variants with alcohol drinking habits and cardiovascular disease risk factors. Alcohol Clin Exp Res 2008; 32: 1984-91.
15. Meldgaard M, Szecsi PB, Carlsen BC, et al,. A novel multiplex analysis of filaggrin polymorphisms: a universally applicable method for genotyping. Clin Chim Acta 2012; 413: 1488-92.
16. Gjerstorff ML,. The Danish cancer registry. Scand J Public Health 2011; 39: 42-5.
17. Storm HH, Michelsen EV, Clemmensen IH, Pihl J,. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997; 44: 535-9.
18. Pedersen CB,. The Danish civil registration system. Scand J Public Health 2011; 39: 22-5.
19. Kaae J, Thyssen JP, Johansen JD, et al,. Filaggrin gene mutations and risk of basal cell carcinoma. Br J Dermatol 2013; 169: 1162-4.
20. Chen AC, Halliday GM, Damian DL,. Non-melanoma skin cancer: carcinogenesis and chemoprevention. Pathology 2013; 45: 331-41.
21. Jensen AO, Svaerke C, Kormendine FD, et al,. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977-2006). Am J Clin Dermatol 2012; 13: 29-36.
22. Karagas MR, Cushing GL Jr, Greenberg ER, et al,. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85: 683-6.
23. Wu Z, Hansmann B, Meyer-Hoffert U, et al,. Molecular identification and expression analysis of filaggrin-2, a member of the S100 fused-type protein family. PLoS One 2009; 4: e5227.
24. Clausen H, Vedtofte P, Moe D, et al,. Differentiation-dependent expression of keratins in human oral epithelia. J Invest Dermatol 1986; 86: 249-54.
25. Rodu B, Cole P, Mandel JS,. Evaluation of the national toxicology program report on carcinogens. Regul Toxicol Pharmacol 2012; 64: 186-8.
26. Carrillo-Infante C, Abbadessa G, Bagella L, Giordano A,. Viral infections as a cause of cancer (review). Int J Oncol 2007; 30: 1521-8.
27. Mager DL,. Bacteria and cancer: cause, coincidence or cure? A review J Transl Med 2006; 4: 14.
28. Husemoen LL, Skaaby T, Jorgensen T, et al,. No association between loss-of-function mutations in filaggrin and diabetes, cardiovascular disease, and all-cause mortality. PLoS One 2013; 8: e84293.
29. Bender AM, Jorgensen T, Helbech B, et al,. Socioeconomic position and participation in baseline and follow-up visits: the Inter99 study. Eur J Prev Cardiol 2012; 21: 899-905.
30. Strandhagen E, Berg C, Lissner L, et al,. Selection bias in a population survey with registry linkage: potential effect on socioeconomic gradient in cardiovascular risk. Eur J Epidemiol 2010; 25: 163-72.
31. Nohr EA, Frydenberg M, Henriksen TB, Olsen J,. Does low participation in cohort studies induce bias? Epidemiology 2006; 17: 413-18.